Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bone Biologics Prices $5.0 Million Underwritten Public Offering
Bone Biologics Effects 1-for-30 Reverse Stock Split
About · FAQs · StocksCafe © 2024 · Privacy · Terms